Owens & Minor (OMI)
(Delayed Data from NYSE)
$16.48 USD
+1.17 (7.64%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $16.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.48 USD
+1.17 (7.64%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $16.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Zacks News
Edwards Lifesciences' (EW) Global Sales Robust Amid Cost Woes
by Zacks Equity Research
Edwards Lifesciences (EW) is registering robust HemoSphere sales in the United States.
Bruker's (BRKR) Buyout to Expand Mass Spectrometry Prospects
by Zacks Equity Research
Bruker's (BRKR) acquisition of IonSense will reach the DART ionization technology to a wider customer base.
Here's Why You Should Retain Amedisys (AMED) Stock For Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.
Thermo Fisher (TMO) Debuts Raman Spectroscopic Analyzer
by Zacks Equity Research
Thermo Fisher's (TMO) Ramina Process Analyzer allows users to conduct precise in situ Raman measurements in a simple manner with high accuracy.
Quest Diagnostics (DGX) Inks New Diabetic Retinal Imaging Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) new collaboration with IRIS will enhance access to diabetic retinopathy screening in the United States.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) on increased UroLift demand and strong vascular business.
Medtronic (MDT) Reports Positive Findings Backing RDN System
by Zacks Equity Research
Medtronic's (MDT) Symplicity Spyral RDN system demonstrated durable and clinically significant reductions in blood pressure at the SPYRAL HTN-ON MED trial.
Here's Why Owens & Minor (OMI) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Owens & Minor (OMI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
AMN Healthcare (AMN) Stock Moves Up 12.9%: What's Driving It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) strong segmental performance and upbeat first-quarter guidance.
Is Owens & Minor (OMI) a Great Stock for Value Investors?
by Zacks Equity Research
Is Owens & Minor (OMI) a great pick from the value investor's perspective right now? Read on to know more.
The Zacks Analyst Blog Highlights Owens & Minor, Thermo Fisher Scientific, Medtronic and Becton, Dickinson and Co.
by Zacks Equity Research
Owens & Minor, Thermo Fisher Scientific, Medtronic and Becton, Dickinson and Co. have been included in this Analyst Blog.
3 Stocks to Focus on With MedTech M&A Scaling New Heights
by Riya Anand
MedTech stocks like Owens & Minor (OMI), Thermo Fisher (TMO) and Medtronic (MDT) are prudent investment choices given their long-term growth potential with recent M&A deals.
Cardiovascular Systems' (CSII) Low Procedure Volume Dents Sales
by Zacks Equity Research
Cardiovascular Systems (CSII) notes that recovery from the Delta variant has been suppressed by the emergence of the highly contagious Omicron variant.
Zimmer Biomet (ZBH) New WalkAI Model to Bolster Robotics Arm
by Zacks Equity Research
WalkAI adds powerful predictive analytic capabilities to ZBEdge, Zimmer Biomet's (ZBH) suite of integrated digital and robotic technologies.
Here's Why You Should Hold on to LabCorp (LH) Stock For Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) better-than-expected results and robust base business performance.
Allscripts (MDRX) Unveils Newly Rebranded App Expo Site
by Zacks Equity Research
Allscripts' (MDRX) rebranded App Expo site to offer developers an opportunity to present their certified solutions online.
Here's Why You Should Retain Syneos Health (SYNH) For Now
by Zacks Equity Research
Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental performance.
Quest Diagnostics (DGX) Base Sales Recover Amid Price Woe
by Zacks Equity Research
Quest Diagnostics (DGX) raises 2022 guidance based on the continued rebound in base business and recent investments expected to accelerate growth.
Allscripts (MDRX) Inks Divestment Deal to Focus on Core Wing
by Zacks Equity Research
Constellation Software will purchase the net assets of Allscripts' (MDRX) Hospitals and Large Physician Practices business segment via its wholly-owned subsidiary.
Bio-Rad's (BIO) Product Launches Aid Growth, Global Arm Strong
by Zacks Equity Research
Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.
Alcon (ALC) Expands in the U.S. With New Clareon IOLs Launch
by Zacks Equity Research
With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.
Here's Why You Should Retain Chemed (CHE) Stock For Now
by Zacks Equity Research
Investors are optimistic about Chemed's (CHE) better-than-expected earnings and robust performance by the Roto-Rooter arm.
Here's Why You Should Retain SmileDirectClub (SDC) For Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub's (SDC) strategic collaborations and product launches.
ResMed's (RMD) SaaS Arm Strength Aids Growth, Supply Woes Stay
by Zacks Equity Research
ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.
Medtronic (MDT) to Gain From New Reimbursement Program for CGM
by Zacks Equity Research
Ontario government's new comprehensive reimbursement program for CGM will enhance access to Medtronic's (MDT) integrated CGM technology for type 1 diabetes patients.